Sutro Biopharma (NASDAQ:STRO) Bolsa

SUTRO BIOPHARMA INC

Sutro Biopharma

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Sutro Biopharma Inc

Strong

STRONG GLOBAL ENTMT INC CL A COM VOTING SHS

Stroeer SE & Co KGaA

STROEER SE CO UNSP/ADR by Stroeer SE and Co

Stronghold Digital Mining Inc

Stronghold Token

STROUD RESOURCES LTD by Stroud Resources Ltd.

Stroud Resources Ltd

FrontView REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVR#NYSE">FVR</a>) affirms FY2025 FFO guidance from $1.20-$1.26 to $1.20-$1.26 vs $1.16 analyst estimate..

News

Guidance

FrontView REIT Affirms FY2025 FFO Guidance of $1.20-$1.26 vs $1.16 Est

Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) is looking for FY2025 Adj EPS of $(1.80)-$(1.51) vs $(1.58) analyst estimate. sees sales of $85.000 million-$95.000 million vs $90.30 million analyst estimate.

SPIR

Spire Global Sees FY2025 Adj EPS $(1.80)-$(1.51) vs $(1.58) Est; Sees Sales $85.000M-$95.000M vs $90.30M Est

Galiano Gold (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GAU#TSX">GAU</a>) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.02 by 50 percent. This is a 66.67 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $76.59 million which beat the analyst consensus estimate of $71.00 million by 7.87 percent. This is a 141.65 percent increase over sales of $31.70 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

TSX:GAU

Galiano Gold Q1 Adj. EPS $0.01 Misses $0.02 Estimate, Sales $76.59M Beat $71.00M Estimate

Galiano Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GAU#AMEX">GAU</a>) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.04 by 75 percent. This is a 66.67 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $76.59 million which beat the analyst consensus estimate of $71.00 million by 7.87 percent. This is a 16.75 percent increase over sales of $65.60 million the same period last year.

Galiano Gold Q1 Adj. EPS $0.01 Misses $0.04 Estimate, Sales $76.59M Beat $71.00M Estimate

North American (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOA#NYSE">NOA</a>) reported quarterly earnings of $0.36 per share which missed the analyst consensus estimate of $0.77 by 53.25 percent. This is a 37.93 percent decrease over earnings of $0.58 per share from the same period last year. The company reported quarterly sales of $237.43 million which missed the analyst consensus estimate of $310.16 million by 23.45 percent. This is a 7.74 percent increase over sales of $220.37 million the same period last year.

North American Q1 Adj. EPS $0.36 Misses $0.77 Estimate, Sales $237.43M Miss $310.16M Estimate

Offerings

PNBK

Patriot National Bancorp Files For Mixed Shelf Offering Up To $250M

Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) has outperformed the market over the past 5 years by 26.92% on an annualized basis producing an average annual return of 41.93%. Currently, Fair Isaac has a market capitalization of $51.75 billion. 
Buying $1000 In FICO: If an investor had bought $1000 of FICO stock 5 years ago, it would be worth $5,797.86 today based on a price of $2125.90 for FICO at the time of writing.
<h3>Fair Isaac's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747258221_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

FICO

Here's How Much $1000 Invested In Fair Isaac 5 Years Ago Would Be Worth Today

Stantec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STN#NYSE">STN</a>) lowers FY2025 Adj EPS guidance from $3.67-$3.76 to $3.57-$3.67 vs $5.23 analyst estimate. Lowers FY2025 sales outlook from $4.49 billion-$4.61 billion to $4.37 billion-$4.50 billion vs $6.50 billion estimate.

Stantec Lowers FY2025 Adj EPS Guidance from $3.67-$3.76 to $3.57-$3.67 vs $5.23 Est; Lowers FY2025 Sales Guidance from $4.49B-$4.61B to $4.37B-$4.50B vs $6.50B Est

Knightscope (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) reported quarterly losses of $(1.28) per share which beat the analyst consensus estimate of $(1.40) by 8.57 percent. This is a 67.92 percent increase over losses of $(3.99) per share from the same period last year. The company reported quarterly sales of $2.92 million which beat the analyst consensus estimate of $2.49 million by 17.35 percent. This is a 29.41 percent increase over sales of $2.25 million the same period last year.

KSCP

Knightscope Q1 EPS $(1.28) Beats $(1.40) Estimate, Sales $2.92M Beat $2.49M Estimate

California Water Service Group Files For Common Stock Offering Of Up To $350M

Natural Alternatives Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAII#NASDAQ">NAII</a>) reported quarterly losses of $(0.37) per share. This is a 37.04 percent decrease over losses of $(0.27) per share from the same period last year. The company reported $28.77 million in sales this quarter. This is a 14.44 percent increase over sales of $25.14 million the same period last year.

NAII

Natural Alternatives Intl Q3 EPS $(0.37) Down From $(0.27) YoY, Sales $28.77M Up From $25.14M YoY

Stantec (TSX:<a class="ticker" href="https://www.benzinga.com/stock/STN#TSX">STN</a>) affirms FY2025 Adj EPS guidance from $5.13-$5.26 to $5.13-$5.26 vs $5.24 analyst estimate. Affirms FY2025 sales outlook from $6.28 billion-$6.45 billion to $6.28 billion-$6.45 billion vs $6.53 billion estimate.

TSX:STN

Stantec Affirms FY2025 Adj EPS Guidance of $5.13-$5.26 vs $5.24 Est; Affirms FY2025 Sales Guidance of $6.28B-$6.45B vs $6.53B Est

Management

LAZR

Luminar Technologies Appoints Paul Ricci As CEO, Effective On Or About May 21, 2025

WIIM

GCTS

GCTS stock has given up its prior loss. GCT Semiconductor shares were trading lower after the company reported worse-than-expected Q1 financial results.

Luminar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) released its first-quarter results after Wednesday's closing bell. Here's a look at the key figures from the quarter. 
The Details:  Luminar Technologies reported quarterly losses of $1.50 per share, which beat the analyst consensus estimate of losses of $1.78. Quarterly revenue came in at $18.89 million, which beat the Street estimate of $15.98 million.
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/05/45414265/nvidia-climbs-on-saudi-ai-investments-analyst-estimates-15-billion-to-20-billion-in-revenue?utm_source=articleShare">Nvidia Climbs On Saudi AI Investments: Analyst Estimates $15 Billion To $20 Billion In Revenue&nbsp;</a>
Luminar announced a new operating plan enabled by a unified product architecture. The company expects it will reduce quarterly non-GAAP opreational expenditures by approximately half by the end of fiscal 2025 versus the beginning of fiscal 2024.
&#8220;In a world of macro uncertainty and adversity, we&#8217;re firing on all cylinders to ramp up production, ramp down costs and capitalize on the future, as evidenced by our announcements today,&#8221; said CEO Austin Russell.
&#8220;This kicks off our new operating plan for Luminar with a unified product platform, enabling radical focus and streamlining of the business, as well as unlocking value throughout our organization.&#8221;
LAZR Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Luminar Technologies stock was down 1.68% at $4.68 after-hours on Wednesday.  
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45353123/quantum-stocks-are-hot-in-2025-biggest-movers-to-watch?utm_source=articleShare">Quantum Stocks Are Hot In 2025: Biggest Movers To Watch&nbsp;</a></li>
</ul>
Image: Shutterstock

Movers

Tech

Luminar Technologies Shares Slip After Q1 Results, New Operating Plan

Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) lowers FY2025 sales outlook from $29.00 million-$32.00 million to $26.00 million-$30.00 million vs $33.43 million estimate.

BNGO

Bionano Genomics Lowers FY2025 Sales Guidance from $29.00M-$32.00M to $26.00M-$30.00M vs $33.43M Est

Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) sees Q2 sales of $6.300 million-$6.800 million vs $7.02 million analyst estimate.

Bionano Genomics Sees Q2 Sales $6.300M-$6.800M vs $7.02M Est

Dick's Sporting Goods shares are trading lower after WSJ reported the company is near a deal to buy Foot Locker.

Foot Locker shares are trading higher after WSJ reported Dick's Sporting Goods nears deal to buy the company.

<a href="https://www.wsj.com/business/deals/dicks-sporting-goods-nears-deal-to-buy-foot-locker-7ecf9194?msockid=21c662101c496b42343370ae1de86aaa">https://www.wsj.com/business/deals/dicks-sporting-goods-nears-deal-to-buy-foot-locker-7ecf9194?msockid=21c662101c496b42343370ae1de86aaa</a>

Comments

Sutro Biopharma

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL